Inner Mongolia Furui Medical Science Co., Ltd. (SHE:300049)
55.95
+4.55 (8.85%)
May 8, 2026, 3:04 PM CST
SHE:300049 Revenue
Inner Mongolia Furui Medical Science had revenue of 360.14M CNY in the quarter ending March 31, 2026, with 9.00% growth. This brings the company's revenue in the last twelve months to 1.63B, up 19.79% year-over-year. In the year 2025, Inner Mongolia Furui Medical Science had annual revenue of 1.60B with 18.26% growth.
Revenue (ttm)
1.63B
Revenue Growth
+19.79%
P/S Ratio
9.12
Revenue / Employee
1.72M
Employees
946
Market Cap
14.83B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.60B | 246.37M | 18.26% |
| Dec 31, 2024 | 1.35B | 195.28M | 16.93% |
| Dec 31, 2023 | 1.15B | 144.97M | 14.37% |
| Jan 1, 2023 | 1.01B | 110.28M | 12.27% |
| Jan 1, 2022 | 898.48M | 90.95M | 11.26% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chengzhi | 10.87B |
| Anhui Anke Biotechnology (Group) | 2.56B |
| Tibet Cheezheng Tibetan Medicine | 2.42B |
| Vcanbio Cell & Gene Engineering Corp., | 1.42B |
| Jinyu Bio-technology | 1.39B |
| Hualan Biological Vaccine | 1.20B |
| Chengdu Olymvax Biopharmaceuticals | 774.47M |
| Mabwell (Shanghai) Bioscience | 745.32M |